Trial Profile
A pivotal trial of BTG945 (CT900)
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 17 Oct 2018
Price :
$35
*
At a glance
- Drugs Idetrexed (Primary)
- Indications Ovarian cancer; Solid tumours
- Focus Registrational; Therapeutic Use
- Sponsors Carrick Therapeutics
- 17 Oct 2018 New trial record
- 11 Oct 2018 According to a The Institute of Cancer Research media release, the trial will be led by Dr Susanna Banerjee at The Royal Marsden NHS Foundation Trust.